Company intelligence / Profile preview
Weben Pharma
Hangzhou, Zhejiang, Chinawebenpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Weben Pharma’s lead candidate, WBC100, is a first-in-class small molecule degrader of c-Myc, showing potent anti-tumor activity in preclinical models and currently in a Phase 1 trial for relapsed/refractory acute myeloid leukemia and advanced solid tumors. Dose escalation is ongoing and expansion is anticipated; early results demonstrate regression of c-Myc overexpressing tumors with good tolerability[4][5][6][8].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeDegradable Molecular Glue
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Collaboration with Zhejiang University (clinical trial sponsor)[5][8]
Beyond the preview
Go deeper on Weben Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Weben Pharma.